Nova Chemdrugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 23 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.85 Cr
- Revenue Growth 14.09%
- Profit Growth 205.97%
- Ebitda 28.39%
- Net Worth 17.62%
- Total Assets 97.18%
About Nova Chemdrugs
Nova Chemdrugs Private Limited (NCPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 December 2001 and has a history of 23 years and one month. Its registered office is in Pune, Maharashtra, India.
The Corporate was formerly known as Nova Chemdrugs Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.85 Cr.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232MH2001PTC108616
-
Company No.
108616
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Dec 2001
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Nova Chemdrugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Viraj Shah
|
Director | 15-Oct-2015 | Current |
|
Rajen Shah
|
Director | 06-Dec-2001 | Current |
|
Meghana Shah
|
Director | 29-Nov-2023 | Current |
Financial Performance of Nova Chemdrugs.
Nova Chemdrugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.09% increase. The company also saw a substantial improvement in profitability, with a 205.97% increase in profit. The company's net worth Soared by an impressive increase of 17.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nova Chemdrugs?
In 2021, Nova Chemdrugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Raptim Research Private LimitedRajen Shah, Viraj Shah and 1 more are mutual person
-
Citus Research LlpRajen Shah and Viraj Shah are mutual person
Charges (Loans)
₹58.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 5.85 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2021 | Others | ₹5.80 Cr | Open |
| 06 Dec 2021 | Others | ₹0.50 M | Open |
How Many Employees Work at Nova Chemdrugs?
Unlock and access historical data on people associated with Nova Chemdrugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nova Chemdrugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nova Chemdrugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
